The successful reinspection by the FDA is a critical regulatory milestone for Alvotech, likely leading to increased investor confidence and potential for future product approvals. This news directly impacts Alvotech and is highly relevant to the company's operations and future prospects. The positive outcome is likely to be viewed favorably by investors, hence the short-term positive impact on the stock price.